Gilead becomes insitro's first major partner in deal potentially worth over $1bn
Executive Summary
Machine learning and big data start-up insitro signed its first major deal, penning an agreement with Gilead Sciences Inc. for the discovery and development of new treatments for nonalcoholic steatohepatitis (NASH).
Deal Industry
- Digital Health
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice